%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R ] /Count 1 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 13 0 R /GS2 14 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260301221731+00'00') /ModDate (D:20260301221731+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 11 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 4877 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics and University Health Network Sign)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Licensing Agreement for pre-clinical biologic and small)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(molecule assets)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(NEW YORK and HONG KONG and TORONTO , April 6, 2022 /PRNewswire/ ?? Treadwell)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(Therapeutics today announced that it has entered into a license agreement with the University Health)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(Network \(UHN\) in Toronto, Canada for four novel oncology target programs, including a deep estate of)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(pre-clinical therapeutic candidates including both antibodies and small molecules. These programs)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(were initiated and validated by the therapeutics team at UHN??s Campbell Family Institute at the)] TJ ET BT 35.000 595.757 Td /F1 12.0 Tf [(Princess Margaret Cancer Centre, which previously drove the development of Treadwell??s small)] TJ ET BT 35.000 581.105 Td /F1 12.0 Tf [(molecule pipeline from concept to clinic. The terms of the agreement, as well as the identity of the)] TJ ET BT 35.000 566.453 Td /F1 12.0 Tf [(targets, were not disclosed.)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(??It is extremely gratifying to have the opportunity to build on the legacy of innovation represented in)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(these programs within Treadwell. This expansion of our preclinical pipeline aligns with Treadwell??s)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(commitment to continue to deliver effective, first-in-class therapeutic options for cancer patients. We)] TJ ET BT 35.000 495.845 Td /F1 12.0 Tf [(look forward to further validating these assets and selecting a development candidate for the most)] TJ ET BT 35.000 481.193 Td /F1 12.0 Tf [(advanced program in 2022.?)] TJ ET BT 194.420 481.193 Td /F1 12.0 Tf [()] TJ ET BT 197.756 481.193 Td /F1 12.0 Tf [( said Dr. Mark Bray, Treadwell CSO and co-founder. ??Our goal at)] TJ ET BT 35.000 466.541 Td /F1 12.0 Tf [(Treadwell is to leverage novel scientific insight into a multi-modality pipeline. With small molecule, cell)] TJ ET BT 35.000 451.889 Td /F1 12.0 Tf [(therapy and now biologic candidates, we are well on our way to achieving that goal.?)] TJ ET BT 491.228 451.889 Td /F1 12.0 Tf [()] TJ ET BT 494.564 451.889 Td /F1 12.0 Tf [( added Dr.)] TJ ET BT 35.000 437.237 Td /F1 12.0 Tf [(Michael Tusche, Treadwell co-CEO.)] TJ ET BT 35.000 410.585 Td /F1 12.0 Tf [(??We are pleased to expand our commercialization partnership further with Treadwell, a UHN spinout)] TJ ET BT 35.000 395.933 Td /F1 12.0 Tf [(company, with these newest license deals. Treadwell??s deeply experienced team is a sound choice)] TJ ET BT 35.000 381.281 Td /F1 12.0 Tf [(to be taking UHN??s world-class medical technologies forward,?)] TJ ET BT 391.124 381.281 Td /F1 12.0 Tf [()] TJ ET BT 394.460 381.281 Td /F1 12.0 Tf [( says Mark Taylor, Director,)] TJ ET BT 35.000 366.629 Td /F1 12.0 Tf [(Commercialization at UHN.)] TJ ET BT 35.000 335.944 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 306.754 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 292.102 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 277.450 Td /F1 12.0 Tf [(The Company??s internally developed clinical pipeline includes CFI-400945 \(PLK4 inhibitor\), CFI-)] TJ ET BT 35.000 262.798 Td /F1 12.0 Tf [(402257 \(TTK inhibitor\), and CFI-402411 \(HPK1 inhibitor\). For more information, please visit)] TJ ET BT 35.000 248.146 Td /F1 12.0 Tf [(www.treadwelltx.com.)] TJ ET BT 35.000 217.462 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 188.271 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 185.661 m 87.020 185.661 l S 0.000 0.000 0.800 rg BT 35.000 173.619 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 171.009 m 137.192 171.009 l S 0.000 0.000 0.000 rg BT 35.000 146.967 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 132.315 Td /F1 12.0 Tf [(April 10, 2022)] TJ ET q 35.000 129.385 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Annot /Subtype /Link /F 28 /A 12 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 171.2884 137.1920 183.4984 ] >> endobj 12 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 14 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj xref 0 15 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000337 00000 n 0000000366 00000 n 0000000515 00000 n 0000000637 00000 n 0000005566 00000 n 0000005673 00000 n 0000005782 00000 n 0000005895 00000 n 0000006028 00000 n 0000006105 00000 n 0000006162 00000 n trailer << /Size 15 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 6219 %%EOF